Biochemist (antibacterials, lipolytic enzyme inhibitors, medicinal chemistry) at the "Lipolysis & Bacterial Pathogenicity" team @canaanlab @lism_cnrs_amu
Marseille, France
Joined September 2018
- Tweets725
- Following66
- Followers121
- Likes1.2K
J.-F. Cavalier retweeted
The June Issue of #ACSInfectiousDIseases is out today!
go.acs.org/ejT
In the cover story by Tian et. al., electrostatic design drives antibiotics to bacterial targets and locks them into a high‑affinity inhibitory state.
Thèse Emma Forest linkedin.com/pulse/th%25C3%2… via @LinkedIn
J.-F. Cavalier retweeted
Mycobacterium tuberculosis cell surface lipids play multifaceted roles in infection, immune evasion, intracellular persistence, granuloma formation and more. What are the latest insights on "the lipid language of tuberculosis?" Find out in #mBio: asm.social/2Oq
ALT Overview of Mtb-phagocyte interactions depicting the diverse functions altered by Mtb lipids.
J.-F. Cavalier retweeted
Very happy to share our group’s second publication this month!
In this work, we investigate the intrinsic anti-tuberculosis activity of polymeric β-cyclodextrin nanoparticles.
Proud of the team’s efforts!
sciencedirect.com/science/ar…
J.-F. Cavalier retweeted
Check out this Review, published in ACS Chemical Biology: “Click Chemistry Methodology: The Novel Paintbrush of Drug Design”.
Find out more: go.acs.org/d6w
#ClickChemistry #DrugDesign #Biotech #Innovation #ACSChemBio
ALT “Click Chemistry Methodology: The Novel Paintbrush of Drug Design”, a Review published in ACS Chemical Biology
J.-F. Cavalier retweeted
Great start to the day at #FEMS2025! Emma Forrest gave an excellent talk on S. aureus biofilms and oxadiazolones against resistant infections. @FEMSmicro
J.-F. Cavalier retweeted
Tuberculosis has reclaimed the position as the top infectious disease killer.
#ACSInfectiousDiseases has dedicated a new Special Issue to how to combat this deadly disease 🦠
Read the issue ➡ go.acs.org/cSV
ALT ACS Infectious Diseases Special Issue Combating Tuberculosis: Obstacles, Innovations, and the Road Ahead
J.-F. Cavalier retweeted
Big news!🦠Pathogens and Disease is becoming FEMS Infectious Diseases starting Jan 2026.
Prof. Gad Frankel, Imperial College London, will become sole Editor-in-Chief as FEMS Journals enters a new chapter with a new name and mission.
Learn more: buff.ly/4tiZzcC
J.-F. Cavalier retweeted
New online! Antimicrobial peptides: structure, functions and translational applications nature.com/articles/s41579-0…
J.-F. Cavalier retweeted
New online! Mycobacterium tuberculosis biology, pathogenicity and interaction with the host nature.com/articles/s41579-0…
Today is a great day!
Our article accepted on March 19, 2025 is published in @journal_mlife.
Great collaborative work with JM Bolla's lab, @MaP_Proteomique @canaanlab @LISM_CNRS_AMU
Céline Crauste from @IBMM_Balard, and more...
👉 onlinelibrary.wiley.com/doi/…
J.-F. Cavalier retweeted
Our work identifying new covalent inhibitors of Staphylococcus aureus serine hydrolyses from fragment libraries is out! great work by
@tulsiupadhyay.bsky.social and our many collaborators, including @christianslentz.bsky.social, @mfellnerlab.bsky.social.
link.springer.com/article/10…
It is my real pleasure to share our ASAP article published in ACS Infect Dis.
Another great collaboration with @PSantTB @canaanlab @LISM_CNRS_AMU @KremerLaurent1 @MaP_Proteomique
@IBMM_Balard
and more...
pubs.acs.org/doi/10.1021/acs…
J.-F. Cavalier retweeted
Inédit: 80 chercheurs s'engagent pour faire de la recherche contre la tuberculose une priorité européenne !
Alors que l’UE adopte le programme de recherche Horizon Europe pour 2026-2027, 80 chercheurs et chercheuses, aux côtés d’Action Santé Mondiale, appellent la France à faire de la tuberculose une priorité stratégique de la R&I européenne.
La tuberculose tue encore plus de 1,25 million de personnes chaque année, bien qu’elle soit évitable et guérissable. Les outils actuels sont largement dépassés : traitements longs, diagnostics peu efficaces, vaccin centenaire… Et la résistance aux antimicrobiens continue de progresser.
Et si nous faisions enfin de la tuberculose une priorité d’innovation en Europe ?
Accédez à la lettre et découvrez les signataires :
actionsantemondiale.fr/app/u…
@IAVI
#EndTB #HorizonEurope #EU4GlobalHealth #SantéMondiale #RechercheEtInnovation #AMR
J.-F. Cavalier retweeted
Excited to share our latest work on incorporating an antiviral molecule into delivery vectors to target pulmonary infections. 🍃🦠
sciencedirect.com/science/ar…
⚠️ @LISM_CNRS_AMU @canaanlab ⚠️
Synthesis and Anti-mycobacterial Activity of Novel Medium-chain β-Lactone Derivatives: A Multi-Target Strategy to combat Mycobacterium abscessus - now published in RSC Medicinal Chemistry pubs.rsc.org/en/content/arti…
Happy to share our new article in Current Research in Microbial Sciences @LISM_CNRS_AMU @canaanlab
Collaborative work with @PriscilleBrodin @MarescaMarc @tasiemskiaurel1 @boidinceline @lindaoyama and more, on the use of antimicrobial peptides against Mtb.
sciencedirect.com/science/ar…
J.-F. Cavalier retweeted
PhD Students - How to review a research paper?
Here is how you can review a research paper.
𝟏. 𝐒𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐜𝐞 - 𝐈𝐬 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐢𝐦𝐩𝐨𝐫𝐭𝐚𝐧𝐭?
- Does it address an important problem?
- Is the target user of this research identified?
- How other researchers and practitioners will benefit from it?
𝑊ℎ𝑒𝑟𝑒 are these 𝑎𝑛𝑠𝑤𝑒𝑟𝑠?
𝐼𝑛𝑡𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛 + 𝐷𝑖𝑠𝑐𝑢𝑠𝑠𝑖𝑜𝑛
------------------------------------------------------
Want to receive human-like review for your paper?
Try Review-it: review-it.ai
A tool that
- identifies the strengths of your paper
- identifies the weaknesses of your paper
- Fix weaknesses in your paper
-------------------------------------------------------
𝟐. 𝐍𝐨𝐯𝐞𝐥𝐭𝐲 - 𝐈𝐬 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐧𝐞𝐰?
- How different this research is from other state-of-the-art papers?
- Is the novelty clearly positioned with respect to related works?
- Is the gap clearly presented and justified? 𝑊ℎ𝑒𝑟𝑒 are 𝑡ℎ𝑒𝑠𝑒 𝑎𝑛𝑠𝑤𝑒𝑟𝑠?
𝐼𝑛𝑡𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛 + 𝑅𝑒𝑙𝑎𝑡𝑒𝑑 𝑊𝑜𝑟𝑘 + 𝐷𝑖𝑠𝑐𝑢𝑠𝑠𝑖𝑜𝑛
𝟑. 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐦𝐞𝐭𝐡𝐨𝐝𝐨𝐥𝐨𝐠𝐲 - 𝐈𝐬 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐜𝐚𝐫𝐫𝐢𝐞𝐝 𝐨𝐮𝐭 𝐢𝐧 𝐭𝐡𝐞 𝐜𝐨𝐫𝐫𝐞𝐜𝐭 𝐰𝐚𝐲?
- Is the selection of research methodology clearly justified?
- Is there something that can lead to faulty results?
- Is the selection of data correct and justified? - Is the design of the case study correct?
- Is the choice of the experimental setup correct and justified?
𝑊ℎ𝑒𝑟𝑒 are 𝑡ℎ𝑒𝑠𝑒 𝑎𝑛𝑠𝑤𝑒𝑟𝑠?
𝑅𝑒𝑠𝑒𝑎𝑟𝑐ℎ 𝑀𝑒𝑡ℎ𝑜𝑑𝑜𝑙𝑜𝑔𝑦
𝟒. 𝐕𝐞𝐫𝐢𝐟𝐢𝐚𝐛𝐢𝐥𝐢𝐭𝐲 - 𝐂𝐚𝐧 𝐨𝐭𝐡𝐞𝐫 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡𝐞𝐫𝐬 𝐯𝐞𝐫𝐢𝐟𝐲 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡?
- Is sufficient information provided for other researchers to verify the claimed contributions?
- Is enough information provided so that other researchers can replicate the reported findings?
- Are the study design steps clearly defined to replicate the findings?
𝑊ℎ𝑒𝑟𝑒 are 𝑡ℎ𝑒𝑠𝑒 𝑎𝑛𝑠𝑤𝑒𝑟𝑠?
𝑅𝑒𝑠𝑒𝑎𝑟𝑐ℎ 𝑚𝑒𝑡ℎ𝑜𝑑𝑜𝑙𝑜𝑔𝑦 + 𝑅𝑒𝑠𝑢𝑙𝑡𝑠
𝟓. 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧 - 𝐈𝐬 𝐭𝐡𝐞 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐩𝐫𝐞𝐬𝐞𝐧𝐭𝐞𝐝 𝐢𝐧 𝐭𝐡𝐞 𝐫𝐢𝐠𝐡𝐭 𝐰𝐚𝐲?
- Is this paper well-written, well-structured, and easy to understand?
- Does this paper contain appropriate figures, tables, and graphs, etc?
- Does every paragraph contain a key message?
- Is this paper free from typo and grammar issues? 𝑊ℎ𝑒𝑟𝑒 are 𝑡ℎ𝑒𝑠𝑒 𝑎𝑛𝑠𝑤𝑒𝑟𝑠? 𝑇ℎ𝑟𝑜𝑢𝑔ℎ𝑜𝑢𝑡 𝑡ℎ𝑒 𝑝𝑎𝑝𝑒𝑟
Anything you'd like to add?
Great work of @DarghamTonia with @KremerLaurent1 @PSantTB @PoncinIsabelle @MaP_Proteomique and more!
@LISM_CNRS_AMU
Happy to share our last paper published in m bio.
A proteomic and functional view of intrabacterial lipid inclusion biogenesis in mycobacteria | mBio journals.asm.org/doi/10.1128…
